Roland Wilhelm Kolbeck - 01 Aug 2026 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: ACRS
Reported as of: 01 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2026, 17:03:20 UTC
Prior SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Rothman, Attorney-in-Fact

Key filing fact

Roland Wilhelm Kolbeck filed Form 4 for Aclaris Therapeutics, Inc. (ACRS) on 04 Aug 2026.

Key facts

This page summarizes Roland Wilhelm Kolbeck's Form 4 filing for Aclaris Therapeutics, Inc. (ACRS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2026, 17:03.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002076327 Primary reporting owner

Kolbeck Roland Wilhelm

Relationship: Chief Scientific Officer
Address: C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE
Signature: /s/ Matthew Rothman, Attorney-in-Fact
Signature date: 04 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRS transaction

Common Stock

Options Exercise

Transaction value
Shares: +36,375
Change %
Price
Shares after: 36,375
Date: 01 Aug 2026
Ownership: Direct
Footnotes: F1

ACRS transaction

Common Stock

Tax liability

Transaction value
Shares: -12,385
Change %: -34%
Price: $5.20^*
Shares after: 23,990
Date: 01 Aug 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -36,375
Change %: -25%
Price: $0.000000^*
Shares after: 109,125
Date: 01 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 36,375
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Footnote F2

The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

Footnote F3

The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.